Antimicrobial susceptibility testing of Acinetobacter spp. by NCCLS broth microdilution and disk diffusion methods

被引:55
作者
Swenson, JM [1 ]
Killgore, GE [1 ]
Tenover, FC [1 ]
机构
[1] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Epidemiol & Lab Branch, Atlanta, GA USA
关键词
D O I
10.1128/JCM.42.11.5102-5108.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Although both broth microdilution (BMD) and disk diffusion (DD) are listed by NCCLS as acceptable methods for testing Acinetobacter spp. for antimicrobial susceptibility, few studies have compared the results generated by the two methods. We tested 196 isolates of Acinetobacter spp. from nine U.S. hospitals and from the Centers for Disease Control culture collection by using BMD and DD and clinically appropriate antimicrobial agents. Categorical results for amikacin, ciprofloxacin, gatifloxacin, gentamicin, imipenem, levofloxacin, meropenem, tobramycin, and trimethoprim-sulfamethoxazole were comparable for the two methods: there was only one very major (VM) error, with tobramycin, and only one major (M) error, with meropenem, when DD results were compared with BMD results. However, VM errors were frequent with the beta-lactams and beta-lactam-beta-lactam inhibitor combinations, while M errors were often observed with tetracyclines. For BMD, tests frequently exhibited subtle growth patterns that were difficult to interpret, especially for beta-lactams. If subtle growth (i.e., granular, small button, or "starry" growth) was considered positive, error rates between BMD and DD were unacceptably high for ampicillin-sulbactam (VM error, 9.8%; minor [m] error, 16.1%), piperacillin (VM error, 5.7%; m error, 13.5%), piperacillin-tazobactam (VM error, 9.3%; m error, 12.9%), ceftazidime (VM error, 6.2%; In error, 11.4%), cefepime (VM error, 6.2%; m error, 13.0%), cefotaxime (m error, 21.2%), ceftri-axone (m error, 23.3%), tetracycline (M error, 11.4%; m error, 32.1%), and doxycycline (M error, 2.6%). When subtle growth patterns were ignored, the agreement still did not achieve acceptable levels. To determine if the problems with BMD testing occurred in other laboratories, we sent frozen BMD panels containing beta-lactam drugs and nine isolates to six labs with experience in performing BMD and DD. Among these laboratories, cefepime MICs ranged from less than or equal to8 to greater than or equal to32 mug/ml for four of the nine strains, confirming the problem in interpreting BMD results. Discrepancies between the categorical interpretations of BMD and DD tests were noted primarily with cefepime and piperacillin, for which the BMD results were typically more resistant. Clinical laboratories should be aware of these discrepancies. At present, there are no data to indicate which method provides more clinically relevant information.
引用
收藏
页码:5102 / 5108
页数:7
相关论文
共 22 条
[1]  
[Anonymous], [No title captured]
[2]   Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii [J].
Corbella, X ;
Ariza, J ;
Ardanuy, C ;
Vuelta, M ;
Tubau, F ;
Sora, M ;
Pujol, M ;
Gudiol, F .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (06) :793-802
[3]   Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: Project ICARE phase 2 [J].
Fridkin, SK ;
Steward, CD ;
Edwards, JR ;
Pryor, ER ;
McGowan, JE ;
Archibald, LK ;
Gaynes, RP ;
Tenover, FC .
CLINICAL INFECTIOUS DISEASES, 1999, 29 (02) :245-252
[4]   Phenotypic antimicrobial resistance patterns in Pseudomonas aeruginosa and Acinetobacter:: results of a Multicenter Intensive Care Unit Surveillance Study, 1995-2000 [J].
Friedland, I ;
Stinson, L ;
Ikaiddi, M ;
Harm, S ;
Woods, GL .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2003, 45 (04) :245-250
[5]   Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients:: Geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999) [J].
Gales, AC ;
Jones, RN ;
Forward, KR ;
Liñares, J ;
Sader, HS ;
Verhoef, J .
CLINICAL INFECTIOUS DISEASES, 2001, 32 :S104-S113
[6]   Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: Review of available interpretative criteria and quality control guidelines [J].
Gales, AC ;
Reis, AO ;
Jones, RN .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (01) :183-190
[7]   Genetic and functional analysis of the chromosome-encoded carbapenem-hydrolyzing oxacillinase OXA-40 of Acinetobacter baumannii [J].
Héritier, C ;
Poirel, L ;
Aubert, D ;
Nordmann, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (01) :268-273
[8]   In vitro activities of the β-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with β-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains [J].
Higgins, PG ;
Wisplinghoff, H ;
Stefanik, D ;
Seifert, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (05) :1586-1592
[9]   Multiresistant Acinetobacter infections:: a role for sulbactam combinations in overcoming an emerging worldwide problem [J].
Levin, AS .
CLINICAL MICROBIOLOGY AND INFECTION, 2002, 8 (03) :144-153
[10]  
National Committee for Clinical Laboratory Standards (NCCLS), 2000, NCCLS document M2-A7, V7th